The inspection, which was conducted from March 10 to 14, 2025, has been classified as ‘No Action Indicated,’ meaning the FDA found no objectionable conditions or practices during its review. Shares of Zydus Lifesciences Ltd ended at ₹979.10, down by ₹2.50, or 0.25%, on the BSE.
